| rPET production line | 1.0 line |
|---|
BSE filing, NSE: GANECOS. Summary written from the filing by ALFA Finder's alert engine.
Ganesha Ecosphere Ltd: key numbers
- Share price
- ₹995.80
- Market cap
- ₹2,668 Cr
- Revenue (annual)
- ₹1,482 Cr
- Net profit (annual)
- ₹38.21 Cr
- P/E (TTM)
- 47.2×Sector 49.8×
- Promoter holding
- 39.33%+0.00% QoQ
- FII holding
- 10.71%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ganesha Ecosphere Ltd
All →Ganesha Ecosphere Board Meeting Date
Ganesha Ecosphere schedules a 31 October 2026 board meeting for unaudited quarterly and half-yearly results. Trading window closed from 01 October until 48 hours after results.
Ganesha Ecosphere Other Announcement
Ganesha Ecosphere Ltd has submitted its quarterly shareholding pattern for the quarter ended September 30, 2026, in compliance with SEBI Listing Regulations.
Ganesha Ecosphere Other Announcement
Ganesha Ecosphere Limited submitted the Regulation 74(5) compliance certificate from its Registrar and Share Transfer Agent for the quarter ended September 30, 2026.
Ganesha Ecosphere Employee Stock Options
Ganesha Employee Welfare Trust acquired 1,653 shares and sold 110 shares of Ganesha Ecosphere Ltd via open market transactions.
Ganesha Ecosphere Management Change
Ganesha Ecosphere Ltd announced the appointment of Mr. Rajiv Kumar Saxena as a Non-Executive Independent Director, approved by shareholders at the 37th AGM.
Ganesha Ecosphere Annual General Meeting
Ganesha Ecosphere Limited conducted its 37th Annual General Meeting via video conferencing on September 17, 2026, to seek shareholder approval on various resolutions.
Other regulatory approval announcements
All →Vedavaag Systems Regulatory Approval
Vedavaag's WOS received IRDAI Certificate of Registration to act as Direct Life & General Insurance Broker. The group enters regulated insurance broking activity.
Hikal Regulatory Approval
Hikal's Bengaluru API facility received a Swissmedic GMP Certificate of Compliance. The certification supports wider access to European and other regulated markets.
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
RNFI Services Regulatory Approval
RNFI received RBI no-objection to acquire control of Smart Payment Solutions Private Limited. Remaining tranches may proceed, but no transaction value is disclosed.
Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.